RxDoctor Payments Data

Anjala Pahwa, MD

Family Medicine · Wilmington, DENPI 1841365012

Payments from drug & device makers

$967in general payments, 2019–2025

Across 54 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$121
  • AstraZeneca$94
  • Pfizer$92
  • Astellas Pharma US Inc$88
  • GSK$84
  • Lilly USA, LLC$65
  • plus $422 from 13 others

What the payments were for

  • Food & beverage$967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$967 in reported general payments places this provider in the 65th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$254,547
Medicare patients
338
Services billed
3,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin137$155,116
OzempicSemaglutide84$127,085
EliquisApixaban85$57,544
TrulicityDulaglutide18$33,856
JanuviaSitagliptin Phosphate26$29,407
FarxigaDapagliflozin Propanediol19$23,437
XareltoRivaroxaban22$21,392
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,977
Arnuity ElliptaFluticasone Furoate33$11,145
VascepaIcosapent Ethyl13$9,984
Advair HfaFluticasone Propion/Salmeterol21$8,778
Breo ElliptaFluticasone/Vilanterol13$8,169
Rosuvastatin Calcium380$7,955
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,439
Atorvastatin Calcium381$5,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$155,116137 claims
Novo NordiskOzempic$39$127,08584 claims
PfizerEliquis$92$57,54485 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta, Anoro Ellipta$84$38,72979 claims
Lilly USA, LLCTrulicity$65$33,85618 claims
MerckJanuvia$13$29,40726 claims
AstraZenecaFarxiga$94$23,43719 claims
Johnson & JohnsonXarelto$14$21,39222 claims
AbbVieSynthroid$51$4,09153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →